Načítá se...
Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral
SUMMARY: A 72-year-old man with no history of diabetes was referred to our department due to hyperglycemia during pembrolizumab treatment for non-small-cell lung carcinoma. His blood glucose level was 209 mg/dL, but he was not in a state of ketosis or ketoacidosis. Serum C-peptide levels persisted a...
Uloženo v:
| Vydáno v: | Endocrinol Diabetes Metab Case Rep |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Bioscientifica Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7219158/ https://ncbi.nlm.nih.gov/pubmed/32478673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-19-0152 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|